Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPH4336 + letrozole versus placebo + letrozole as first-line treatment for HR-positive, HER2-negative advanced or metastatic breast cancer
CTR20230211Phase 2Active
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SPH4336 in breast cancer, sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Started Apr 2023; status: active.
02
Drugs
SPH4336
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20230211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230211.